Teva Moves Forward With LAI Olanzapine Trials

Triggers Payment For Partner MedinCell, After Risperidone Knocked Back By US FDA

 
• By David Wallace
  
Injectable syringe vial blue liquid
Teva and MedinCell are developing olanzapine and risperidone LAIs • Source: Shutterstock

More from Value Added Medicines

More from Products